In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds
Open Access
- 16 October 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (12) , 6477-6488
Abstract
Cytochrome P450 46A1 (CYP46A1) is a central nervous system-specific enzyme, which catalyzes cholesterol 24-hydroxylation. Currently CYP46A1 is being evaluated in a clinical trial for activation by small doses of the anti-HIV drug efavirenz. Eight efavirenz-related compounds were investigated for CYP46A1 activation in vitro, induction of a CYP46A1 spectral response and spectral Kd values, interaction with the P450 allosteric sites, and a model of binding to the enzyme active site. We gained insight into structure-activity relationships of efavirenz for CYP46A1 activation and found that the investigated efavirenz primary metabolites are stronger and better activators of CYP46A1 than efavirenz. We also established that CYP46A1 is activated by racemates and that a conformational-selection mechanism is operative in CYP46A1. The results suggest structural modifications of efavirenz to further increase CYP46A1 activation without inhibition at high compound concentrations. It is possible that not only efavirenz but its metabolites activate CYP46A1 in vivo.Keywords
Funding Information
- National Eye Institute (EY011373)
- National Institute on Aging (AG067552)
- National Institute of General Medical Sciences (R01 GM062882, R01 GM118122)
This publication has 71 references indexed in Scilit:
- The Male Genital Tract Is Not a Pharmacological Sanctuary From EfavirenzClinical Pharmacology & Therapeutics, 2011
- Efavirenz concentrations in CSF exceed IC50 for wild-type HIVJournal of Antimicrobial Chemotherapy, 2010
- Structural Basis of Drug Binding to CYP46A1, an Enzyme That Controls Cholesterol Turnover in the BrainJournal of Biological Chemistry, 2010
- Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-HydroxylationDrug Metabolism and Disposition, 2010
- Adeno-associated Virus Gene Therapy With Cholesterol 24-Hydroxylase Reduces the Amyloid Pathology Before or After the Onset of Amyloid Plaques in Mouse Models of Alzheimer's DiseaseMolecular Therapy, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brainProceedings of the National Academy of Sciences, 2008
- Use of complementary cation and anion heavy-atom salt derivatives to solve the structure of cytochrome P450 46A1Acta Crystallographica Section D Structural Biology, 2008
- Efavirenz Does Not Interact with the ABCB1 Transporter at the Blood—Brain BarrierPharmaceutical Research, 2006